Escipram

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Escipram

Escipram is a prescription-only medication whose active ingredient is Escitalopram, a compound utilized to help manage mood and emotional stability. The drug is classified by health authorities as a Selective Serotonin Reuptake Inhibitor (SSRI), denoting its specific action within the brain's chemical signaling pathways.


Property Description
Active ingredient Escitalopram (as Escitalopram oxalate)
Form Film-coated tablets, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating mood and anxiety levels
Origin Synthetic, refined S-enantiomer

Classification and Identity of the Active Ingredient

Escipram is a psychotropic drug that belongs to the SSRI class. The core active substance is Escitalopram, which is recognized as a highly specific, pure S-enantiomer (single isomer) synthesized from its related precursor, citalopram. This chemical refinement results in targeted activity toward the serotonin system. As a single active ingredient product (monotherapy), Escipram's mechanism relies entirely on Escitalopram to function within the Central Nervous System (CNS), which is a key differentiating factor from combination medications.

General Purpose and Available Preparations

The general purpose of Escitalopram is to restore a more regulated emotional state by influencing the availability of the neurotransmitter serotonin (5-HT). The drug helps sustain communication between neurons by inhibiting the rapid reabsorption (reuptake) of serotonin by nerve cells. The overall aim is to provide therapeutic support to relieve persistent sadness or excessive worry by stabilizing mood, without addressing specific diagnoses or instructions for use.

Escitalopram is administered via the oral Route of administration and is available in two main Dosage form(s). Patients typically receive the medication as a film-coated tablet or, alternatively, as an oral solution dissolved in an aqueous solution base, offering flexibility in patient administration.

What side effects are possible with Escipram?

Possible Side Effects and Safety Information

Escipram (escitalopram) carries a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (up to age 24) during initial treatment and dose adjustments. Monitoring for clinical worsening and unusual behavioral changes is essential.

Common and Less Common Adverse Reactions

The most frequently reported adverse reactions include nausea, headache, insomnia, somnolence, increased sweating, dry mouth, diarrhea, fatigue, and sexual dysfunction (e.g., decreased libido, anorgasmia, ejaculation disorder).

Serious and Clinically Significant Risks

Escipram may cause serious adverse reactions that require immediate medical attention. These include the potentially life-threatening Serotonin Syndrome, particularly when used with other serotonergic agents. Other serious risks involve QTc-interval prolongation and the potential for a dangerous heart rhythm known as Torsade de Pointes; this is a dose-dependent effect, and the drug is contraindicated in patients with a known prolonged QT interval.

Hyponatremia (low sodium levels), sometimes due to the Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH), has been reported, especially in elderly patients. Escipram may also increase the risk of seizures and abnormal bleeding (e.g., bruising, purpura), particularly when used concurrently with drugs that affect blood clotting.

Population-Specific Safety Notes

Elderly patients are at an increased risk of hyponatremia. Caution is advised when treating patients with a history of mania or hypomania due to the risk of activation. Pregnant patients and nursing mothers should use Escipram only after careful consideration of potential risks to the infant or fetus. Abrupt discontinuation of the drug should be avoided; a gradual dose taper is recommended to minimize discontinuation symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medication can be serious and is defined by symptoms affecting the Central Nervous System (CNS) and the Cardiovascular system.

Documented Overdose Symptoms

The clinical manifestations of an overdose, as described in regulatory documents, can include:

  • CNS Effects: Dizziness, tremor, agitation, somnolence, and in severe cases, convulsions or coma.
  • Cardiovascular Effects: Tachycardia (rapid heartbeat), changes in blood pressure, and prolongation of the QTc interval, which is an electrical change in the heart that may lead to serious arrhythmias like Torsade de Pointes.
  • Serotonin Syndrome: Overdose can lead to Serotonin Syndrome, a potentially life-threatening condition.

Overdose Severity and Risk Factors

While fatalities are rare when the medication is taken alone, the risk of a severe or fatal outcome is notably increased in cases of mixed overdose involving alcohol or other drugs. Even if symptoms appear mild or absent, an overdose is considered potentially serious due to the risk of delayed cardiac and CNS events.

Required Emergency Action

Immediate medical attention is required for any suspected overdose. Because there is no specific antidote, treatment involves supportive and symptomatic care in a hospital setting. Healthcare professionals will focus on establishing and maintaining an adequate airway, ensuring ventilation, and closely monitoring vital signs, including continuous cardiac monitoring. You must immediately call the poison control helpline or seek emergency medical help.

Therapeutic Uses of Escipram

Therapeutic Support for Persistent Depressed Mood

The medication is commonly used to address conditions marked by persistent sadness, low mood, and the loss of interest or pleasure in daily activities (anhedonia). It supports emotional regulation, helping to ease the overall symptom burden and assists with maintaining functional stability for those dealing with affective disorders. Escipram is relevant for easing symptoms associated with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), and is also applied in therapeutic domains presenting with panic disorder and Obsessive Compulsive Disorder (OCD).


Moderating Excessive Worry and Chronic Anxiety

The medication is relevant in clinical settings involving chronic, pervasive, and difficult-to-control worry and associated physical symptoms like restlessness and muscle tension. It contributes to easing the overall symptom load during periods of heightened symptoms, which supports patients during difficult episodes by easing distress.


Managing Acute Panic and Compulsive Patterns

Escipram is applied in therapeutic domains presenting with recurrent, acute episodes of debilitating fear and may assist with managing symptomatic manifestations of intrusive, unwanted thoughts and repetitive behaviors characteristic of the anxiety spectrum. It assists with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Pervasive Emotional Distress The medication is considered relevant in conditions characterized by periods of heightened symptoms and supports the patient by easing the overall symptom load across emotional and cognitive domains.

Eligibility and Restrictions for Use

Escipram (escitalopram) is primarily approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults. Its use may also be indicated for other conditions like obsessive-compulsive disorder (OCD) and panic disorder, depending on a healthcare provider's evaluation.

Who Can Use Escipram?

Patient Group Indication
Adults MDD, GAD, and certain other anxiety/mood disorders
Adolescents (12-17 years) Treatment of MDD (in some jurisdictions and under strict medical supervision)

Who Should Not Use Escipram?

Escipram is contraindicated for individuals with specific pre-existing conditions or those taking particular medications. Individuals who should generally avoid Escipram include:

  • Patients with a known hypersensitivity or allergic reaction to escitalopram or citalopram.
  • Those currently taking or who have recently (within 14 days) stopped taking Monoamine Oxidase Inhibitors (MAOIs), due to the risk of serotonin syndrome.
  • Individuals using Pimozide or other medications known to significantly prolong the QT interval on an electrocardiogram, as Escipram itself can cause dose-dependent QT prolongation.
  • Patients with certain heart rhythm problems (congenital long QT syndrome) or uncorrected electrolyte imbalances (e.g., low potassium or magnesium).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Escipram (Escitalopram) establishes strict constraints regarding co-administration with other substances.

Contraindicated Combinations

Concomitant use is contraindicated with Pimozide due to the risk of QT interval prolongation and with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue. These MAOI combinations are prohibited due to the risk of developing Serotonin Syndrome. A mandatory separation of at least 14 days is required when switching between Escipram and a psychiatric MAOI.

Pharmacodynamic and Metabolic Interactions

Co-administration with other serotonergic agents, such as Triptans, Lithium, or the herbal product St. John's Wort, increases the regulatory-documented risk of Serotonin Syndrome. An increased risk of abnormal bleeding is noted when Escipram is co-administered with drugs that interfere with hemostasis, including NSAIDs, Aspirin, and Warfarin.

Escipram is officially documented as a CYP2D6 inhibitor, which can increase the plasma concentration of other medicines metabolized by this enzyme (e.g., Desipramine). Conversely, inhibitors of CYP2C19 and CYP3A4 (such as Cimetidine) may increase the drug's own exposure. Food does not affect the absorption of Escipram, but Alcohol may contribute to additive CNS effects.

Mechanism of Action

How Escipram Works

Direct Molecular Target and Inhibition

Escipram functions as a selective inhibitor of serotonin (5-HT) reuptake. Its primary biological target is the serotonin transporter (SERT), a protein located on the presynaptic neuronal membrane. Escipram binds to and blocks the action of SERT, preventing it from transporting 5-HT out of the synaptic cleft and back into the presynaptic neuron.


Cascade: Synaptic Neurotransmitter Modulation

The immediate consequence of SERT blockade is a measurable increase in the extracellular concentration of 5-HT within the synaptic cleft. This elevated level of 5-HT then leads to enhanced binding and stimulation of post-synaptic receptors. The resulting modulation of post-synaptic activity represents the molecular cascade that ultimately alters the overall signaling kinetics and neural circuit function.

Dosage and Administration Information

Escipram (escitalopram) is administered orally and must be taken once daily, either in the morning or the evening. It can be taken with or without food.

Official Dosing and Administration Protocol

Administration Scope Official Labeled Instruction
Route of Administration Oral
Frequency and Timing Once daily; morning or evening; with or without food.
Adult Starting Dose 10 mg once daily
Maximum Adult Dose 20 mg once daily
Preparation Requirements The oral solution must be diluted with water, orange juice, or apple juice prior to use.

Dose Adjustment and Specific Populations

The initial adult dose is 10 mg once daily. If a dose increase is necessary, it must occur after a minimum interval of no less than one week. For most elderly patients (over 65 years) and patients with hepatic impairment, the maximum recommended daily dose is 10 mg.

Discontinuation of Treatment

To discontinue Escipram, a gradual dose reduction is recommended whenever possible. The dose should be tapered instead of being stopped abruptly.

Missed Dose

If a dose is missed, the patient should skip the missed dose and take the next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Escipram

Evidence for Use in Major Depressive Disorder (MDD)

Escipram was studied for Major Depressive Disorder (MDD) in research primarily conducted in the form of short-term randomized controlled trials (RCTs). These studies were conducted on nonpsychotic adult outpatients and used standardized scales to monitor changes in symptom intensity over defined time intervals, typically lasting 8 to 12 weeks. Comparative studies where Escipram was observed in a research context against a placebo or against other existing treatments was frequently used in this research context.

Findings derived from these short-term studies, and synthesized across larger pooled data analyses, data show patterns related to symptom measurements in the studied populations. Specifically, the research highlights changes measured on depression rating scales during the study period. Studies have also monitored outcomes reflecting daily functioning, research contributes to the broader evidence landscape regarding patient-reported experiences over this brief time frame.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Escipram was studied for Generalized Anxiety Disorder (GAD) using various randomized, controlled trial designs. The research examined adult outpatients and, in some cases, focused on children and adolescents. Studies explored outcomes related to episodic or acute changes in anxiety, using scales like the Hamilton Anxiety Rating Scale (HAMA) to track symptom intensity or variability.

Studies monitored how scores on these anxiety scales changed in the group receiving Escipram compared to the placebo group over observation periods of 8 to 12 weeks for acute treatment. These findings describe group patterns related to outcomes reflecting daily functioning, research provides insight into short-term changes.

What is Still Uncertain About Escipram Research

Data for certain groups, such as pregnant populations or those with significant or complex medical comorbidities, remain insufficient due to trial exclusion criteria. Long-term effects are not fully established; there is limited information for long-term outcomes and durability of any observed patterns across multiple years of use. Furthermore, while research provides context, study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. NICE Guideline: Depression in adults: recognition and management.

Frequently Asked Questions (FAQ)

Common questions about Escipram (FAQ)


Q: How long does Escipram usually take to start working?

According to official drug information, it may take several weeks before a patient feels the full therapeutic benefit of Escipram. Continuation of treatment is often described as necessary even if immediate improvement is not noticeable.


Q: Can Escipram affect my ability to drive or operate machinery?

Official labeling documents state that Escipram may interfere with certain cognitive and motor performance abilities. Official warnings suggest caution is necessary regarding activities that require alertness, such as driving a motor vehicle or operating heavy machinery.


Q: Is it common to feel worse when first starting Escipram?

Regulatory warnings require monitoring for new or worsening anxiety, agitation, and unusual behavioral changes, especially when beginning therapy or following a change in dosage. This monitoring is required by regulatory documents when starting this type of treatment.


Q: Is Escipram considered habit-forming or addictive?

No, Escipram (escitalopram) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). However, stopping the medicine suddenly may cause withdrawal-like symptoms, often referred to as discontinuation syndrome, and official guidance recommends a gradual dose reduction for discontinuation.


Q: How is the safety of Escipram reviewed by regulatory agencies?

Agencies like the FDA review the safety and efficacy of Escipram based on extensive data from clinical trial submissions. They also mandate post-marketing surveillance and studies to continue tracking safety profiles and submitting final safety reports after the medicine is on the market.


Q: Is Escipram available as a generic medicine?

Yes, regulatory records, such as the FDA's Approved Drug Products list (Orange Book), confirm that generic versions of Escipram, known as escitalopram oxalate tablets, are available.


Q: Does Escipram affect blood pressure?

Official safety data lists orthostatic hypotension (a drop in blood pressure when rising from sitting or lying down) as a potential risk. In rare cases, extremely high blood pressure has also been reported as a symptom of the potentially serious condition called Serotonin Syndrome.


Q: Is it normal to have vivid dreams when taking Escipram?

Yes, official product information, including post-marketing reports, lists abnormal dreams as a reported undesirable effect. This means it is an effect that patients have frequently reported during clinical trials or after the medicine was released.


Q: What information is usually given in official patient leaflets for Escipram?

Official patient leaflets, such as the FDA Medication Guide, typically summarize the most critical safety information. This includes details on serious warnings (like suicidality and Serotonin Syndrome), common side effects, and essential instructions for use and missed doses.


Q: Does Escipram interact with grapefruit or grapefruit juice?

Regulatory information indicates that grapefruit or its juice may lead to a moderate interaction with Escipram. This is because grapefruit can inhibit the metabolic enzyme CYP3A4, potentially increasing the amount of medicine in the body.


Q: Why do some people feel more anxious when they first start taking this medicine?

Regulatory documents state that anxiety and restlessness are documented potential adverse effects. These symptoms are sometimes observed, particularly at the beginning of treatment or when the dosage of the medicine is changed.


Q: What is the purpose of the patient Medication Guide for Escipram?

The Medication Guide is required by the FDA for certain medicines to provide essential risk-based information to patients. It educates them about the proper use of the drug and highlights the most important risk-based information.


Q: Is it possible to be allergic to Escipram?

Yes, regulatory documents list the possibility of allergic reactions to the medicine. Documented risks include hypersensitivity to escitalopram or citalopram, and rare, severe reactions such as anaphylaxis.


Q: What is the time frame for expecting the full effects of Escipram?

According to official product information, it may take several weeks before a patient feels the full therapeutic benefit of Escipram. Continuation of treatment is often described as necessary even if immediate improvement is not noticeable.


Q: Are there any official restrictions on activities while taking Escipram?

Regulatory labeling advises caution regarding any activities that require full mental alertness. Restrictions pertain to activities like driving or operating heavy machinery until the individual's response to the medicine and its impact on performance are known.


Q: Is Escipram a controlled substance?

No, Escipram is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is not subject to the same strict prescribing and storage rules as medicines with a high potential for dependence or abuse.


Q: Can Escipram be used for panic attacks?

Official European regulatory documents list Major Depressive Disorder and Generalized Anxiety Disorder as documented indications. Some international jurisdictions list Panic Disorder as an approved indication for this medicine.

How should Escipram be stored and disposed of?

Storage and Disposal of Escitalopram (Escipram)

Storage Requirements

Official regulatory labeling dictates that Escitalopram tablets must be stored at 25 C (77 F), with temperature excursions permitted between 15 C and 30 C. To maintain stability, the container must be kept tightly closed and may require a light-resistant container. It is mandatory to store the medication in a secure location that is out of the reach and sight of children.

Disposal Instructions

Unused, expired, or unwanted Escitalopram product must be disposed of in accordance with local requirements. Government guidance advises against discarding the medicine via wastewater or household waste. Patients should consult a pharmacist or local regulatory body for specific instructions on pharmaceutical waste programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Escipram found in:

A-Z Index: